A personal note of the corresponding author: The author, Joshua Weissgarten, an outstanding personality, clinical nephrologist, investigator, educator and medical director, passed away on June 3, 2012 at the age of 63, shortly after acceptance of this manuscript.
1525-139X/asset/olbannercenter.gif?v=1&s=31bd21532938c94b3455abef15a75d9b98218560)
Editorial
N-Acetylcysteine Use for Amelioration of Aminoglycoside-Induced Ototoxicity in Dialysis Patients
Article first published online: 18 JUN 2012
DOI: 10.1111/j.1525-139X.2012.01090.x
© 2012 Wiley Periodicals, Inc.
Additional Information
How to Cite
Feldman, L., Sherman, R. A. and Weissgarten, J. (2012), N-Acetylcysteine Use for Amelioration of Aminoglycoside-Induced Ototoxicity in Dialysis Patients. Seminars in Dialysis, 25: 491–494. doi: 10.1111/j.1525-139X.2012.01090.x
Publication History
- Issue published online: 20 SEP 2012
- Article first published online: 18 JUN 2012
- Abstract
- Article
- References
- Cited By
Abstract
Use of aminoglycoside antibiotics is associated with significant ototoxicity, especially on patients with decreased renal function. The risk of aminoglycoside ototoxicity may approach 60%. Oxidative stress has been suggested as a general mechanism of aminoglycoside ototoxicity and is prevalent in dialysis population. N-acetylcysteine (NAC) is an effective antioxidant and has been safely used in dialysis patients. New experimental and clinical data, explored in this review, provide a good case to recommend NAC administration to all dialysis patients, receiving aminoglycosides.